Venture capital fund
Every published round MRCF3 took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies MRCF3 has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for MRCF3, as distinct from the investments it has made.
Companies MRCF3 has backed that another company then bought. An exit for the holding, not a deal MRCF3 did.
Stories naming MRCF3. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily